PCR (3 assays, 2 gene targets, no virus recovered, no sequence obtained) from mallards in July (bird banding effort in Utah) and November (hunter harvest in Oregon) during surveillance in 2015–2016. Sequence of the HPAIV H5N2 from a wild mallard during surveillance in 2016–2017, evidence for continued evolution of this virus lineage, widespread detections of HPAIV H5N2 in healthy wild birds (9), and lack of pathobiological effects in experimentally infected waterfowl (10) collectively provide strong evidence for maintenance of HPAIV H5N2 in wild birds in North America. Detection of HPAIV in a mallard might imply the potential for dissemination of HPAIV H5N2 during the southward fall migration of waterfowl in 2016.

Acknowledgments
We thank Michael J. Petrula and David Sinnett for collecting samples; Kerrie Franzen, Meredith Grady, Andrew Hubble for providing technical assistance; the Washington State Animal Disease Diagnostic Laboratory for their participation in wild bird surveillance activities, and the originating and submitting institution (Kagoshima University, Kagoshima, Japan) for A/crane/Kagoshima/KU1/2014(H5N8) sequences (accession no. EPI169390] from the GISAID EpiFlu Database (http://platform.gisaid.org).

Dr. Lee is postdoctoral researcher at the US Department of Agriculture, Athens, GA. His research interests include molecular epidemiology and host–pathogen interactions for avian influenza viruses.

References
1. Winker K, McCracken KG, Gibson DD, Pruett CL, Meier R, Huettemann F, et al. Movements of birds and avian influenza from Asia into Alaska. Emerg Infect Dis. 2007;13:547–52. http://dx.doi.org/10.3201/eid1304.061072
2. Koehler AV, Pearce JM, Flint PL, Franson JC, Ip HS. Genetic evidence of intercontinental movement of avian influenza in a migratory bird: the northern pintail (Anas acuta). Mol Ecol. 2008;17:4754–62. http://dx.doi.org/10.1111/j.1365-294X.2008.03953.x
3. Lee DH, Torchetti MK, Winker K, Ip HS, Song CS, Swayne DE. Intercontinental spread of Asian-origin H5N8 to North America through Beringia by migratory birds. J Virol. 2015;89:6521–4. http://dx.doi.org/10.1128/JVI.00728-15
4. Lee DH, Bahl J, Torchetti MK, Killian ML, Ip HS, DeLiberto TJ, et al. Highly pathogenic avian influenza viruses and generation of novel reassortants, United States, 2014–2015. Emerg Infect Dis. 2016;22:1283–5. http://dx.doi.org/10.3201/eid2207.160048
5. Ramey AM, Reeves AB, Sonsthagen SA, TeSlaa JL, Nashold S, Donnelly T, et al. Dispersal of H9N2 influenza A viruses between East Asia and North America by wild birds. Virology. 2015;482:79–83. http://dx.doi.org/10.1016/j.virology.2015.03.028
6. Lee DH, Park JK, Yuk SS, Erendze-Ochir TO, Kwon JH, Lee JB, et al. Complete genome sequence of a natural reassortant H9N2 avian influenza virus found in bean goose (Anser fabalis): direct evidence for virus exchange between Korea and China via wild birds. Infect Genet Evol. 2014;26:250–4. http://dx.doi.org/10.1016/j.meegid.2014.06.007
7. Ramey AM, Reeves AB, TeSlaa JL, Nashold S, Donnelly T, Bahl J, et al. Evidence for common ancestry among viruses isolated from wild birds in Beringia and highly pathogenic intercontinental reassortant H5N1 and H5N2 influenza A viruses. Infect Genet Evol. 2016;40:176–85. http://dx.doi.org/10.1016/j.meegid.2016.02.035
8. Animal and Plant Health Inspection Service, US Department of Agriculture. Epidemiologic and other analyses of HPAI-affected poultry flocks: September 9, 2015 Report [cited 2016 Oct 28]. https://www.aphis.usda.gov/animal_health/animal_dis/spec/poultry/downloads/Epidemiologic-Analysis-Sept-2015.pdf
9. Bevins SN, Dusek RJ, White CL, Gidlewski T, Bodenstein B, Mansfield KG, et al. Widespread detection of highly pathogenic H5 influenza viruses in wild birds from the Pacific Flyway of the United States. Sci Rep. 2016;6:28980. http://dx.doi.org/10.1038/srep28980
10. Pantin-Jackwood MJ, Costa-Hurtado M, Shepherd E, DeJesus E, Smith D, Spackman E, et al. Pathogenicity and transmission of H5 and H7 highly pathogenic avian influenza viruses in mallards. J Virol. 2016;90:9967–82.

Address for correspondence: Mia K. Torchetti, Animal and Plant Health Inspection Service, National Veterinary Services Laboratories, US Department of Agriculture, 1920 Dayton Ave, Ames, IA 50010, USA; email: mia.kim.torchetti@aphis.usda.gov

Increase in Urgent Care Center Visits for Sexually Transmitted Infections, United States, 2010–2014

William S. Pearson, Guoyu Tao, Karen Kroeger, Thomas A. Peterman

Author affiliation: Centers for Disease Control and Prevention, Atlanta, Georgia, USA

DOI: http://dx.doi.org/10.3201/eid2302.161707

During 2010–2014, urgent care centers saw a 2-fold increase in the number of visits for chlamydia and gonorrhea testing and a 3-fold increase in visits by persons with diagnosed sexually transmitted infections. As urgent care becomes more popular, vigilance is required to ensure proper management of these diseases.

Sexually transmitted infections (STIs) are the most commonly reported nationally notifiable diseases in the United States (1), and annual medical costs for these diseases are estimated to exceed $16 billion (2). Reported rates of gonorrhea, chlamydia, and syphilis all increased from 2014 to 2015, and antimicrobial drug–resistant gonorrhea remains an important concern (3). Therefore, proper diagnosis and
treatment of these diseases is essential to reduce STI-associated morbidity rates and prevent further drug resistance (4).

Urgent care centers have been identified as appropriate sources of care for nonemergency conditions that would otherwise be treated in a more costly emergency department setting (5). These centers are proliferating across the country because of public demand for convenient care and the need to contain healthcare costs (6). The Urgent Care Association of America estimates that >9,000 of these centers are currently operating in the United States and, on average, each center sees ≈14,000 visits per year (7). Additionally, STI clinics are closing across the country because of decreased funding (8); therefore, urgent care centers might increasingly be a typical setting for STI diagnosis and treatment.

We found no literature describing the frequency of diagnosis and treatment of STIs in urgent care settings. Therefore, we set out to estimate the number of visits to urgent care centers for the testing and diagnosis of chlamydia and gonorrhea.

For these analyses, we used data from the MarketScan commercially insured medical claims database for 2010, 2012, and 2014 (9). We only included claims for visits to urgent care centers and aggregated these claims to provide numbers of visits for each patient. We then searched the claims for Current Procedural Terminology (CPT) codes and codes from the International Classification of Diseases, Ninth Revision, that indicated the testing or diagnosis of chlamydia, gonorrhea, or an “unspecified venereal disease” (Table). We counted visits that involved a test or diagnosis for each of the indicated diseases for each year and stratified these results by percentage of female patients and the average age of the patients. We then used weights supplied in the dataset and calculated weighted numbers of visits. All analyses were conducted by using SAS 9.3 (SAS Institute, Cary, NC, USA).

Overall, we estimated a ≈2.5-fold increase during 2010–2014 for all visits to urgent care centers (online Technical Appendix, https://wwwnc.cdc.gov/EID/article/23/2/16-1707-Techapp1.pdf). Among these visits, we observed increases in the numbers of visits that involved STI testing or the treatment of patients with diagnosed STIs. During 2010–2014, a ≈1.5-fold increase occurred in visits that involved chlamydia testing and a ≈2-fold increase in visits involving gonorrhea testing. We observed even larger increases in visits that involved diagnosed STIs. During the same period, we observed a ≈6-fold increase in the numbers of visits that involved

**Table.** Number of urgent care center visits by commercially insured patients during which the patient was tested for gonorrhea or chlamydia or treated for a diagnosed sexually transmitted infection, United States, 2010–2014*

| Characteristic | 2010          | 2012          | 2014          |
|----------------|---------------|---------------|---------------|
| Total visits† | 1,197,720     | 2,603,234     | 4,075,379     |
| Weighted‡     | 47,000,000    | 99,000,000    | 155,000,000   |
| % Female      | 81.5          | 81.7          | 81.9          |
| Average age, y| 30.7          | 35.6          | 36.3          |
| Visits during which a chlamydia test was performed (CPT codes 87110, 87270, 87320, 87490, 87491, 87492, 87810) | | | |
| Unweighted    | 1,293         | 2,090         | 3,711         |
| Weighted      | 51,701        | 76,746        | 136,167       |
| % Female      | 81.8          | 79.4          | 76.6          |
| Average age, y| 31.0          | 29.6          | 30.7          |
| Visits during which a gonorrhea test was performed (CPT codes 87590, 87591, 87592, 87850) | | | |
| Unweighted    | 1,174         | 1,885         | 3,665         |
| Weighted      | 47,747        | 69,665        | 134,403       |
| % Female      | 82.6          | 80.1          | 76.5          |
| Average age, y| 31.2          | 29.8          | 29.9          |
| Visits during which diagnosed chlamydia was treated (ICD-9 codes 079.88, 079.98, 099.41, 099.50–099.56, 099.59) | | | |
| Unweighted    | 133           | 430           | 988           |
| Weighted      | 4,004         | 12,152        | 29,291        |
| % Female      | 59.4          | 56.7          | 61.3          |
| Average age, y| 29.7          | 27.0          | 26.8          |
| Visits during which a diagnosed “unspecified venereal disease” was treated (ICD-9 codes 099.8, 099.9) | | | |
| Unweighted    | 155           | 406           | 1,260         |
| Weighted      | 4,655         | 11,392        | 35,550        |
| % Female      | 55.3          | 49.6          | 50.4          |
| Average age, y| 30.1          | 30.1          | 31.0          |
| Visits during which diagnosed gonorrhea was treated (ICD-9 code 098) | | | |
| Unweighted    | 116           | 224           | 522           |
| Weighted      | 3,000         | 6,074         | 13,783        |
| % Female      | 41.8          | 53.5          | 47.0          |
| Average age, y| 30.3          | 29.1          | 30.2          |

*CPT, Current Procedural Terminology; ICD-9, International Classification of Diseases, Ninth Revision; STI, sexually transmitted infection.†Includes all patients seeking care at urgent care centers for any reason.‡Estimates are rounded to the nearest million.
diagnosed chlamydia, a >3-fold increase in the numbers of visits that involved diagnosed gonorrhea, and a ≈6-fold increase in the numbers of visits that involved an unspecified diagnosed STI. Most visits that involved STI testing were made by female patients; the average age for all patients at these visits was 28.1 years. Most visits by a patient for diagnosed chlamydia were made by female patients; the average age for all patients at these visits was 27.8 years. The number of visits by patients for an unspecified diagnosed STI was nearly evenly split between male and female patients; the average age of all patients at these visit was 30.4 years. The visits for diagnosed gonorrhea were predominantly made by male patients; the average age of all patients at these visits was 29.9 years.

Visits to urgent care centers have increased over time, and our findings demonstrate that visits to urgent care centers for STI care in particular have dramatically increased. Previous work has highlighted differences in the use of antibiotics to treat chlamydia in emergency departments compared with physician offices (10) suggesting that differences might also exist in the treatment of STIs in urgent care centers compared with other healthcare settings. Given the increases in STIs, increases in antimicrobial drug resistance, and increases in use of urgent care centers for STI care, further work is needed to determine how STIs are being managed in this venue to ensure quality care.

Dr. Pearson is a health scientist in the Division of STD Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta. His primary research interests include the organization, financing, and delivery of healthcare services.

References
1. Centers for Disease Control and Prevention. Sexually transmitted disease surveillance 2014. Atlanta: US Department of Health and Human Services; 2015 [cited 2016 Sep 7]. https://www.cdc.gov/std/stats14
2. Owusu-Edusei K Jr, Chesson HW, Gift TL, Tao G, Mahajan R, Ocfemin MC, et al. The estimated direct medical cost of selected sexually transmitted infections in the United States, 2008. Sex Transm Dis. 2013;40:197–201. http://dx.doi.org/10.1097/OLQ.0b013e318285c6d2
3. Centers for Disease Control and Prevention. Sexually transmitted disease surveillance 2015. Atlanta: US Department of Health and Human Services; 2016 [cited 2016 Oct 7]. https://www.cdc.gov/std/stats15
4. Workowski KA, Bolan GA. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015;64(RR-03):1–137.
5. Weinick RM, Burns RM, Mehrotra A. Many emergency department visits could be managed at urgent care centers and retail clinics. Health Aff (Millwood). 2010;29:1630–6. http://dx.doi.org/10.1377/hlthaff.2009.0748
6. Yee T, Lechner AE, Boukus ER. The surge in urgent care centers: emergency department alternative or costly convenience? Res Brief. 2013;26:1–6.
7. American Association of Urgent Care Centers. 2015 Urgent Care Industry Headlines [cited 2016 Aug 21]. http://c.ymcdn.com/sites/www.ucaoa.org/resource/resmgr/Infographics/2015_BM_Survey_Headlines_Sum.pdf
8. Golden MR, Kerndt PR. Improving clinical operations: can we and should we save our STD clinics? Sex Transm Dis. 2010;37:264–5. https://dx.doi.org/10.1097/OLQ.0b013e3181d5e01e
9. Truven Health Analytics. MarketScan database [cited 2016 Sep 7]. https://marketscan.truvenhealth.com/marketscanportal
10. Pearson WS, Gift TL, Leichliter JS, Jenkins WD. Differences in the treatment of Chlamydia trachomatis by ambulatory care setting. J Community Health. 2015;40:1115–21. http://dx.doi.org/10.1007/s10900-015-0037-x

Address for correspondence: William S. Pearson, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Mailstop E80, Atlanta, GA 30329-4027, USA; email: wpearson@cdc.gov
Increase in Urgent Care Center Visits for Sexually Transmitted Infections, United States, 2010–2014

Technical Appendix

**Technical Appendix Figure.** Number of urgent care center visits by commercially insured patients during which the patient was tested for gonorrhea or chlamydia or treated for a diagnosed sexually transmitted infection, United States, 2010–2014.